ResMed (NYSE:RMD) Price Target Raised to $244.00 at Royal Bank Of Canada

ResMed (NYSE:RMD) had its price target hoisted by equities researchers at Royal Bank Of Canada from $234.00 to $244.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “sector perform” rating on the medical equipment provider’s stock. Royal Bank Of Canada’s price target suggests a potential upside of 15.18% from the stock’s current price.

Other equities research analysts have also issued reports about the company. Robert W. Baird set a $213.00 price objective on ResMed in a research note on Friday. KeyCorp cut their price target on ResMed from $260.00 to $255.00 and set an “overweight” rating for the company in a report on Friday. UBS Group restated a “buy” rating and issued a $300.00 price target on shares of ResMed in a research report on Tuesday, July 21st. Morgan Stanley reaffirmed an “equal weight” rating and issued a $230.00 price objective (down from $286.00) on shares of ResMed in a research note on Wednesday, June 17th. Finally, Wells Fargo & Company lowered their price objective on ResMed from $225.00 to $215.00 and set an “equal weight” rating on the stock in a research report on Friday. Seven analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $240.17.

ResMed Stock Performance

Shares of NYSE:RMD traded down $11.39 during trading on Friday, hitting $211.84. The company’s stock had a trading volume of 3,773,819 shares, compared to its average volume of 1,301,783. The company has a 50-day moving average of $200.06 and a 200-day moving average of $222.30. ResMed has a 12 month low of $180.26 and a 12 month high of $293.81. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.01 and a quick ratio of 2.33. The firm has a market cap of $30.73 billion, a price-to-earnings ratio of 20.43, a P/E/G ratio of 1.36 and a beta of 0.76.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $2.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.89 by $0.06. ResMed had a net margin of 27.44% and a return on equity of 25.35%. The company had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.46 billion. During the same quarter last year, the firm posted $2.55 earnings per share. The firm’s revenue was up 8.6% compared to the same quarter last year. On average, sell-side analysts expect that ResMed will post 11.14 earnings per share for the current year.

Insider Transactions at ResMed

In other news, CEO Michael J. Farrell sold 4,991 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $218.55, for a total value of $1,090,783.05. Following the transaction, the chief executive officer directly owned 466,223 shares in the company, valued at $101,893,036.65. The trade was a 1.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter C. Farrell sold 8,000 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $225.00, for a total value of $1,800,000.00. Following the completion of the transaction, the director directly owned 52,773 shares of the company’s stock, valued at approximately $11,873,925. This trade represents a 13.16% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 17,982 shares of company stock worth $3,858,837. Insiders own 0.65% of the company’s stock.

Institutional Investors Weigh In On ResMed

Several institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in shares of ResMed in the second quarter worth $2,400,375,000. Deutsche Bank AG bought a new stake in ResMed in the 2nd quarter valued at $257,692,000. Perigon Wealth Management LLC bought a new stake in ResMed in the 2nd quarter valued at $4,597,000. Phillips Wealth Planners LLC purchased a new stake in ResMed in the 2nd quarter worth $247,000. Finally, Trust Co. of Vermont purchased a new stake in ResMed in the 2nd quarter worth $39,000. Institutional investors own 54.98% of the company’s stock.

ResMed News Summary

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: ResMed reported fiscal fourth-quarter earnings of $2.95 per share, above the roughly $2.89–$2.90 consensus and up from $2.55 a year earlier. Revenue rose 8.6% year over year to $1.46 billion, matching estimates. ResMed Q4 Earnings and Revenues Top Estimates
• Positive Sentiment: The company raised its quarterly dividend by 10% to $0.66 per share, payable September 24 to shareholders of record August 20. The increase supports ResMed’s income-investment appeal and signals confidence in cash generation. ResMed posts strong Q4 earnings and lifts dividend
• Neutral Sentiment: ResMed’s profitability remained strong, with a 27.44% net margin and 25.35% return on equity, but the earnings beat was largely offset by concerns about forward growth. ResMed Q4 2026 earnings call transcript
• Negative Sentiment: Analysts reduced their targets and maintained cautious ratings: Piper Sandler cut its target to $225 with a neutral rating, while Wells Fargo lowered its target to $215 and assigned an equal-weight rating. These actions suggest limited near-term upside after the guidance concerns. Analyst price-target changes
• Negative Sentiment: Fiscal 2027 revenue guidance came in below consensus expectations, raising concerns that growth could moderate even as demand for ResMed’s sleep and respiratory products remains healthy. RMD stock falls despite Q4 earnings beat
• Negative Sentiment: Director Peter Farrell sold 8,000 shares for approximately $1.8 million. The sale occurred under a pre-arranged Rule 10b5-1 plan, reducing its significance, but it may add modest selling pressure. SEC insider trading filing

About ResMed

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.